SCHEMBL23426567

SCHEMBL23426567

N#Cc1ccccc1-c1c2ccccc2c(-c2ccc3oc4cccc(-c5c6ccccc6c(-c6ccccc6C#N)c6ccccc56)c4c3c2)c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 12/20 0.39
▸ CYP3A4 P08684 12/20 0.39
▸ ALDH1A1 P00352 11/20 0.39
▸ HSD17B10 Q99714 10/20 0.39
▸ CLK4 Q9HAZ1 8/20 0.39
▸ HPGD P15428 4/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ ESR2 Q92731 1/20 0.37
▸ CYP2C19 P33261 6/20 0.37
▸ LMNA P02545 5/20 0.37
▸ USP2 O75604 4/20 0.37
▸ CYP2D6 P10635 4/20 0.37
▸ KDM4E B2RXH2 4/20 0.36
▸ TSHR P16473 4/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ CYP2C9 P11712 3/20 0.36
▸ BLM P54132 1/20 0.36
▸ TNKS O95271 1/20 0.36
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23426485 0.96 CYP1A2 (0.37) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL26750872 0.91 ALDH1A1 (0.42) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL23427265 0.90 ESR2 (0.37) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL23427490 0.88 TNKS (0.36) CYP1A2CYP3A4ALDH1A1HPGDKDM4E
SCHEMBL23427335 0.86 ESR2 (0.35) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL23427704 0.86 ESR2 (0.35) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL23426935 0.86 ALOX5 (0.40) CYP3A4ALDH1A1HSD17B10HPGDKDM4E
SCHEMBL23427177 0.86 ALDH1A1 (0.40) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL23426866 0.85 ADORA2A (0.41) ALDH1A1HSD17B10TNKSALOX15ALOX5
SCHEMBL23426933 0.85 MAPT (0.45) CYP1A2CYP3A4ALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174560-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-08 — — US disclosed
US-20230165130-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-05-25 — — US disclosed
US-20210249610-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-08-12 — — US disclosed
US-20210167299-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210167299-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CYP1A1, AOX1, OXER1 CYP1A2 15/4885CYP3A4 115/4885ALDH1A1 76/4885
US-20230165130-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CYP1A1, CYP2E1, AOX1 CYP1A2 14/4885CYP3A4 28/4885ALDH1A1 43/4885
US-20230174560-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CRY1, AOX1, CYP1A1 CYP1A2 15/4885CYP3A4 20/4885ALDH1A1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback